The Partnership for Safe Medicines has been publishing information about the counterfeit drug problem around the world for more than a decade. With experts leading the organization and a committed and passionate set of writers and editors, our content is more in-depth than many other sources, which simply copy links to the news from other websites.
In this analysis, which was published in Lexology on October 13, 2020, three global regulatory experts examine barriers to drug importation.
In PSM’s round-up this week: Policy truths about drug importation, prosecutions for fake COVID-19 treatments and financial fraud, and another week in counterfeit pills.
In the first seven months of 2020, the Arizona Department of Health Services reported over 2,700 newly suspected opioid overdose deaths in Arizona. What makes this figure more startling is that there were just over 3,800 suspected opioid deaths in the preceding 30 months. The problem is escalating, and rapidly.
The editorial board of the Florida Times-Union published an op-ed that states that Canadian drug importation will have a limited impact, and is a sign of a broken system, not a solution to one…
Wyoming is one of many states that decided to examine if importing drugs would provide significant savings to its citizens. In a hearing in August and a report released today, they took a critical look at the issue and the Department of Health recommends that the state not pursue the idea for several key reasons…
In PSM’s round-up this week: A new report about the counterfeit medicine trade, fake COVID-19 vaccines in India, the week in counterfeit pills.
In PSM’s round-up this week: HHS defies 20 years of expertise and guidance and recent negative feedback to finalize regulations for state-based Canadian drug importation programs, forward movement on the Safe Therapeutics Act, and more #covidscam and counterfeit drug news.
On September 23, 2020, Department of Health and Human Services Alex Azar submitted a letter to House Minority Leader Kevin McCarthy certifying that Canadian drug importation would pose not additional threats to consumers and would save Americans a significant amount of money on prescription drugs.
Trump Administration Defies 20 Years of FDA Expertise and Guidance in Finalizing Politically Motivated Drug Importation Rule Washington, D.C. (September 24, 2020) – Shabbir Safdar, executive director of the Partnership for Safe Medicines, released the following statement in response to the Trump Administration’s Final Rule issued today on the importation of prescription drugs: “With 40…
On September 24th, 2020 the U.S. Department of Health and Human Services released a draft of finalized rulemaking for Importation of Prescription Drugs. Watch this space for the most up-to-date news.